This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.
Researchers at Stanford have developed a porous biologics-loaded multimaterial construct, called Hybrid Tissue Engineering Construct (HyTEC), with applications in regenerative medicine and therapeutic delivery.
Based on their proprietary HyTEC tissue engineering platform, researchers at Stanford have developed an osteoinductive intramedullary implant (IM) device for improved bone healing.
Researchers at Stanford have developed a biodegradable device and platform carrier of biologics for promoting faster bone healing of large bone defects, fractures, and non-union.
Mature pancreatic islets are the gold standard for transplantation-based approaches for islet replacement in type 1 and type 3c diabetes mellitus (T1D and T3cD), but this feature is offset by the scarcity of human cadaveric pancreas donors.
Stanford researchers have developed chemically modified AAV vectors through an unnatural amino acid substitution on the capsid surface for post-production vector engineering through biorthogonal copper-free click chemistry.
The Nicolls Lab at Stanford University has discovered P-selectin inhibitors as a possible treatment for lymphedema. Lymphedema affects more than 200 million people in the world and currently has no approved pharmacological therapies.
Stanford researchers in the Benson Lab have developed CCSNet, an open source software platform for modeling CO2 storage reservoirs based on machine learning neural networks.
Stanford inventors have developed an early-stage screening method to diagnose abdominal aortic aneurysms (AAA). AAA is a common cardiovascular disease with high prevalence in European men 65 years and above.
Researchers at Stanford have developed a next-generation technique of fabricating metal oxide thin films using open-air ultrasonic spray combustion and plasma curing.